Bivatuzumab mertansine

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.[1]

Bivatuzumab mertansine
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD44 v6
Clinical data
ATC code
  • none
Identifiers
ChemSpider
  • none
 NY (what is this?)  (verify)

References

  1. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. (October 2006). "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical Cancer Research. 12 (20 Pt 1): 6064–72. doi:10.1158/1078-0432.CCR-06-0910. PMID 17062682.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.